Financial Ratios

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01038Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE1238.2540.1 (+3.35 %)
PREV CLOSE ( ) 1198.15
OPEN PRICE ( ) 1200.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 65795
TODAY'S LOW / HIGH ( )1200.65 1245.00
52 WK LOW / HIGH ( )670 1264
NSE1237.4032.1 (+2.66 %)
PREV CLOSE( ) 1205.30
OPEN PRICE ( ) 1205.40
BID PRICE (QTY) 1237.40 (675)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 668011
TODAY'S LOW / HIGH( ) 1202.35 1245.00
52 WK LOW / HIGH ( )669.8 1263.95
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)19.9333.9189.9351.6436.00
   CEPS(Rs)28.9442.1852.3632.8924.80
   DPS(Rs)4.004.008.005.003.00
   Book NAV/Share(Rs)231.66215.84374.67290.11248.25
   Tax Rate(%)32.6219.9017.3316.8818.39
Margin Ratios
   Core EBITDA Margin(%)15.2721.8028.2220.5718.68
   EBIT Margin(%)13.7019.9427.0718.4015.92
   Pre Tax Margin(%)12.9119.7526.8517.9715.34
   PAT Margin (%)8.7015.8222.2014.9412.52
   Cash Profit Margin (%)12.6319.6825.8519.0317.25
Performance Ratios
   ROA(%)6.3712.7920.3813.5310.62
   ROE(%)8.9116.8227.1019.1815.60
   ROCE(%)11.7719.3430.5420.8416.76
   Asset Turnover(x)0.730.810.920.910.85
   Sales/Fixed Asset(x)1.601.741.851.721.52
   Working Capital/Sales(x)1.821.892.322.972.86
Efficiency Ratios
   Fixed Capital/Sales(x)0.620.580.540.580.66
   Receivable days54.9353.6557.3061.4861.61
   Inventory Days107.96110.6398.8797.0596.88
   Payable days83.21103.53123.17125.63140.11
Valuation Parameters
   PER(x)40.6531.2910.5813.4413.65
   PCE(x)27.9925.1618.1721.1019.81
   Price/Book(x)3.504.925.084.783.96
   Yield(%)0.490.380.420.360.31
   EV/Net Sales(x)3.515.014.704.113.49
   EV/Core EBITDA(x)19.7720.9315.2418.1616.79
   EV/EBIT(x)25.4424.9817.2922.2021.78
   EV/CE(x)2.403.644.003.442.83
   M Cap / Sales3.564.984.724.043.44
Growth Ratio
   Net Sales Growth(%)6.835.7017.9020.3112.91
   Core EBITDA Growth(%)-20.76-18.0360.6930.9454.83
   EBIT Growth(%)-26.53-22.0473.0638.9586.45
   PAT Growth(%)-41.22-24.5874.8443.4395.15
   EPS Growth(%)-41.22-62.2974.1543.4394.92
Financial Stability Ratios
   Total Debt/Equity(x)0.240.140.050.120.14
   Current Ratio(x)2.913.123.082.182.25
   Quick Ratio(x)1.921.811.651.161.21
   Interest Cover(x)17.20104.18124.9942.6727.43
   Total Debt/Mcap(x)0.070.030.010.030.04

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.